Related Experiment Videos
Group B streptococcal infection in the neonate
Annals of Clinical and Laboratory Science
|May 1, 1982
Summary
Group B streptococci (GBS) infections, particularly meningitis in newborns, are increasing. Maternal antibodies offer protection, while antibiotic prophylaxis has shown limited efficacy, necessitating further research into vaccines and immunity mechanisms.
Area of Science:
- Neonatal infections
- Bacterial pathogenesis
- Immunology
Background:
- Group B streptococci (GBS) incidence has risen significantly over the past 2-3 decades.
- GBS is a leading cause of neonatal meningitis, with Type III being most prevalent.
- GBS infections present as early-onset (first week) and late-onset (2-20 weeks) syndromes with high mortality rates.
Purpose of the Study:
- To review the current understanding of Group B streptococci (GBS) disease.
- To discuss the efficacy of current prophylactic and therapeutic strategies.
- To highlight areas for future research, including vaccine development.
Main Methods:
- Literature review of GBS epidemiology and disease syndromes.
- Analysis of the effectiveness of antibiotic prophylaxis and maternal antibody protection.
- Discussion of ongoing research into GBS immunity and antigen characterization.
Main Results:
- Antibiotic prophylaxis for GBS has not proven efficacious.
- Maternal antibodies demonstrate protective effects against GBS in neonates.
- Type III GBS is the most common serotype associated with meningitis.
Conclusions:
- Further research is needed to clarify GBS immunity and susceptibility mechanisms.
- Development of a GBS vaccine is a potential prophylactic measure.
- Continued evaluation of antibiotic prophylaxis and therapy is warranted.